fundamental analysis
May 18, 2026
Buffett's four filters — understandable business, favourable economics, able-and-trustworthy management, sensible price — applied step by step to Titan Biotech's FY25 audited numbers, in their canonical sequential order.
April 23, 2026
Charlie Munger's favourite mental model — invert the question. Instead of 'how do I find the next multibagger?', ask 'how do I guarantee small-cap losses?' A disciplined Indian inversion checklist, illustrated by Titan Biotech's FY25 audited numbers.
April 19, 2026
Titan Biotech disclosed only one primary operating segment in FY25, a quiet but powerful sign that the business remains easier to understand and monitor than many small-cap peers.
April 19, 2026
Titan Biotech ended FY25 with an 11-member board, four independent directors, an independent chair, and 14 board meetings - a governance structure that merits serious attention from long-term investors.
